Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12873023 | 0.94 | CTSL (0.46) | CTSLKLK7AGTR2FKBP1AJAK2 | |
| SCHEMBL27264315 | 0.94 | CTSL (0.46) | CTSLKLK7AGTR2FKBP1AJAK2 | |
| SCHEMBL21554728 | 0.90 | CTSL (0.46) | CTSLKLK7AGTR2FKBP1AJAK2 | |
| SCHEMBL18591209 | 0.90 | CTSL (0.46) | CTSLKLK7AGTR2FKBP1AJAK2 | |
| SCHEMBL20539082 | 0.90 | CTSL (0.46) | CTSLKLK7AGTR2FKBP1AJAK2 | |
| SCHEMBL18591210 | 0.90 | CTSL (0.46) | CTSLKLK7AGTR2FKBP1AJAK2 | |
| SCHEMBL30272160 | 0.90 | CTSL (0.46) | CTSLKLK7AGTR2FKBP1AJAK2 | |
| SCHEMBL14544848 | 0.85 | AGTR2 (0.44) | CTSLKLK7AGTR2FKBP1APARP1 | |
| SCHEMBL13201874 | 0.85 | AGTR2 (0.44) | CTSLKLK7AGTR2FKBP1APARP1 | |
| SCHEMBL30704459 | 0.83 | KLK7 (0.45) | CTSLKLK7AGTR2PARP1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154563-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CTSL 469/4885KLK7 606/4885AGTR2 1475/4885 |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | CTSL 469/4885KLK7 606/4885AGTR2 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.